Wizcure Pharmaa recalled 10,080 boxes of Fluorescein Sodium Ophthalmic Strips on December 31, 2025, due to sterility issues. The recall affects products packaged in 100-count and 300-count boxes. Consumers should stop using these products immediately and consult healthcare providers for guidance.
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Consumers and healthcare providers should stop using this product immediately. Contact Wizcure Pharmaa Private Limited or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled products include Fluorescein Sodium Ophthalmic Strips, USP 1mg, packaged in 100-count boxes (NDC 83851-100-10) and 300-count boxes (NDC 83851-100-30). These products were manufactured by Wizcure Pharmaa PVT. LTD in India and distributed nationwide in the USA.
The recall stems from a lack of assurance of sterility. The products were not manufactured in compliance with current good manufacturing practices, posing potential health risks to users.
As of now, no incidents or injuries have been reported related to this recall. The potential health risks associated with using non-sterile ophthalmic strips include infection.
Consumers and healthcare providers should stop using the recalled products immediately. Contact Wizcure Pharmaa Private Limited or your healthcare provider for further guidance.
For more information, contact Wizcure Pharmaa at [phone number not provided]. You can also visit the FDA's website at the following link: https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0350-2026.
Get instant alerts for recalls that affect you. Free forever.
AvKARE recalled Amantadine HCl capsules on February 13, 2026, due to failed dissolution specifications. The recall affects the 100 mg capsules, which may not dissolve properly. Consumers should stop using this product and contact their healthcare provider immediately.
Slate Run Pharmaceuticals recalled Eptifibatide Injection on February 12, 2026. The recall affects all lots of the 75 mg/100 mL vial due to incorrect dosing information. Healthcare providers and consumers must stop using the product immediately.
LEO Pharma Inc. recalled 11,407 units of Adbry injection on February 10, 2026. The recall stems from a lack of assurance of sterility due to particulate matter identified as wool fiber. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Hitachi Ltd. recalled one unit of its Proton Beam Therapy System on February 6, 2026 due to a software anomaly. The issue may result in positional discrepancies during patient treatment. The recall affects distribution in Texas and Washington D.C.
Hitachi recalled its Proton Beam Therapy System on February 6, 2026, due to a software anomaly that may result in positional discrepancies. The recall affects one unit distributed in Texas and Washington D.C. Healthcare providers and patients must stop using the device immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.